Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

2,074.00GBp
8:40am EDT
Change (% chg)

-4.00p (-0.19%)
Prev Close
2,078.00p
Open
2,083.00p
Day's High
2,090.00p
Day's Low
2,073.00p
Volume
155,713
Avg. Vol
654,764
52-wk High
2,703.00p
52-wk Low
1,575.00p

HIK.L

Chart for HIK.L

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The... (more)

Overall

Beta: 1.28
Market Cap(Mil.): £4,986.87
Shares Outstanding(Mil.): 239.93
Dividend: 8.40
Yield (%): --

Financials

  HIK.L Industry Sector
P/E (TTM): 32.28 36.52 36.51
EPS (TTM): 0.64 -- --
ROI: 6.46 14.40 13.85
ROE: 9.67 15.20 14.77

BRIEF-Hikma says first-half revenue up 28 pct

* H1 group core operating profit of $176 mln, down 14 pct and down 3 pct in constant currency

Aug 24 2016

BRIEF-Hikma sees FY revenue between $2-$2.1 bln

* Continue to expect group revenue to be in range of $2.0 bln to $2.1 bln for full year

Aug 03 2016

BRIEF-Hikma says U.S. Court of Appeals upholds regulatory approval of colchicine

* Fda's regulatory approval of hikma's colchicine 0.6 mg capsule product was upheld.

Jul 21 2016

BRIEF-Hikma Pharma announces U.S. launch of two generic tablets

* Announces launch of generic xeloda tablets 150 mg and 500 mg in US Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Jul 20 2016

Court dismisses Takeda's bid to block Hikma gout drug sales

By Brendan Pierson A federal appeals court has dismissed a bid by Takeda Pharmaceutical Co to halt sales of Hikma Pharmaceuticals PLC's gout drug Mitigare, which has the same active ingredient as Takeda's Colcrys.

Jul 15 2016

Hikma seeks dismissal of Takeda's bid to block gout drug sales

Hikma Pharmaceuticals PLC is asking a federal appeals court to reject a bid by rival Takeda Pharmaceutical Co to halt sales of Hikma's gout drug Mitigare, arguing that the challenge is moot after Hikma won a separate patent case last month.

Jun 09 2016

Hikma wins dismissal of Takeda patent lawsuit over gout drug

A federal court has cleared the way for Hikma Pharmaceuticals Plc to continue selling a drug with the same active chemical as Takeda Pharmaceutical Co's gout drug Colcrys, dismissing a patent lawsuit Takeda filed in an effort to keep the drug off the market.

May 20 2016

BRIEF-Hikma Pharma says investors approve directors' pay

* 88.97 pct votes cast at AGM in favour of approval of 2015 remuneration implementation, 11.03 percent against

May 12 2016

BRIEF-Hikma Pharma reiterates guidance for 2016

* Continue to expect full year group revenue to be in range of $2.0 billion to $2.1 billion

May 12 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Sadif Analytics Prime
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.